Warburg Pincus buys India's Integrace as True North, Temasek exit

What's the deal? Warburg Pincus has acquired IntegraceDealroom has a profile for this one. Try Dealroom → Pvt Ltd, an Indian pharmaceutical formulations company focused on orthopedics and gynecology. The US private equity firm announced the deal on July 15, with existing shareholders True North and Temasek fully exiting their investment.

What each side brings: Integrace has built a portfolio of more than 20 brands across high-growth therapeutic markets. Warburg Pincus has backed pharmaceutical and healthcare businesses in India including MetropolisDealroom has a profile for this one. Try Dealroom →, Laurus Labs, MedPlus, and Meril Life Sciences.

New leadership: Industry veteran Rehan Khan will join Integrace as chief executive officer to lead its next phase. Khan was previously managing director at MSD and Abbott India Ltd.

What's the endgame? Warburg Pincus wants to build a scaled pharmaceuticals platform in India. "This acquisition reflects our conviction in therapy-focused, brand-led platforms and our ambition to build a scaled, market-leading pharmaceuticals business in India," said Himanshu Nema, managing director at Warburg Pincus.

Why now? Moneycontrol first reported the firm's majority stake sale plans in September 2025. True North, an early backer, framed the exit as a handover after helping Integrace establish itself among specialists.

The signal: The deal underscores private equity's continued appetite for India's brand-led pharmaceutical businesses, with Warburg Pincus deepening a healthcare portfolio that already spans diagnostics, drugmakers, and medical technology.

Read more: Moneycontrol